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or poor-tolerated AFL Clinical history, other arrhythmias as atrial fibrillation
(AF), data of echocardiography were collected. The patients were followed
from 3 months up to 10 years.
Results: Women tended to be older than men (65.5±12 vs 64±11.5 years)
(p< 0.08). Underlying HD was as frequent in women as in men (76%). HD
nature differed: women had more congenital HD (10 vs 2%, p<0.0001), more
valvular HD (17.5 vs 10% p<0.002) and less respiratory failure (4.5 vs 10%)
(p<0.01), less ischemic HD (5 vs 20%)(p<0.0000) than men. Hypertensive HD,
dilated cardiomyopathy or various HD’s did not differ. Previous history of AF
was more frequent in women (31.5%) than in men (26%) (p<0.012). AFl-
related rhythmic cardiomyopathy tended to be less frequent in women than in
men (4 vs 8%) (p<0.07). Presentation with 1/1 AFl was as frequent in women
as in men (10% vs 7%). AFl ablation-related major complications as complete
AV block, death or cardiac shock were more frequent in women than in men
(4 vs 1%)(p<0.004). After 3±3 years, AFl recurrences tended to be less fre-
quent in women than in men (8.5 vs 13%)(p<0.06). AF occurrence was more
frequent in women than in men (24 vs 14%)(p<0.0002). Among these patients
66% of women and men had no history of AF before AFl ablation. Their risk
of AF remains higher in women than in men (16% vs 8%)(p<0.007).
Conclusions: There gender-related differences in the prevalence, clinical
presentation, ablation-related complications and AF incidence. AFL is less
common in women than in men, despite similar age and as frequent under-
lying HD. The risk of AFl ablation-related major complications is higher in
women than in men. Women have more frequently history of AF and an inde-
pendent higher risk than men of developing AF after ablation of atrial flutter.
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Introduction: Studies have documented the underuse of oral anticoagulant
therapy (OAC) as stroke prophylaxis in older persons with history of atrial
fibrillation (AF). Failure to prescribe OAC is often due to the perception by
physicians of bleeding because of specific older people clinical factors.
We performed a prospective observational study in the University Hospital
of Reims, whose aim was to evaluate the management of thromboembolic risk
in older patients in everyday-life hospital practice and impact of frailty and
dependence objective parameters.
Method: 150 AF patients over 75 years were consecutively included over
a period of four months. Clinical and biological data, risk scores for bleeding
(HASBLED) and thrombo-embolic events (CHADS and CHADSVASc) were
computed. Several scores and parameters of assessment of autonomy and risk
of falling were independently recorded: MMS (Mini-Mental Status), ADL
(Activities of Daily Living) and IADL (Instrumental ADL).
Results: Mean age was 83±13 years (75 men). At discharge, 52.2% of
patients were under OAC. Mean CHADS, CHADSVASc and HASBLED
score were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1; all patients had a CHA
DS VASc score ≥2 and 86% a CHADS ≥2. The HASBLED score was asso-
ciated with non-prescription of anticoagulation (p=0.001), while none of the
thrombo-embolic scores was significantly associated with prescription. Spe-
cific studied parameters are in table.
Conclusion: In our study of everyday practice, there is an underuse of anti-
coagulation in the elderly compared to guidelines, mainly because the percep-
tion of the hemorrhagic risk prevails over the thrombo-embolic risk. Specific
geriatric parameters could help to choose the appropriate therapy.
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Introduction: Age is a major thrombo-embolic risk factor in atrial fibril-
lation (AF), but also a risk factor for bleeding under oral anticoagulation
therapy (OAC). However, it appears that older patients are inadequately
treated with OAC.
The objective of our study was to evaluate the use of OAC in elderly
patients hospitalised in a cardiology department according to current guide-
lines.
Method: Over a 4-month period, 142 patients over 75 years old with his-
tory of AF were included. Clinical and biological data were recorded, and risk
scores for bleeding (HASBLED) and thrombo-embolic events (CHADS2 and
CHA2DS2VASc) were independently assessed after discharge. The differences
between bleeding and thrombo-embolic risk were calculated for each patient.
Patients with OAC at discharge and patients without OAC were compared.
Results: Mean age was 83±13 years (75 men). Mean CHADS, CHADS-
VASc and HASBLED scores were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1.
According to CHADSVASc score and guidelines all of the patients were
eligible for OAC. However 47.8% of patients were not under OAC. Those
patients were older (84.6±0.6 vs. 81.8±0.5; p=0.001), predominantly female
(66 vs. 35%; p=0.001) with a higher serum creatinine (127.3±7.3 vs. 106±6.3;
p=0.03) and HASBLED score (2.7 vs. 2.16; p=0.001). OAC use was not asso-
ciated with CHADS and CHADSVASc scores values.
Conclusion: Our study in daily pratice confirms that OAC in older patients
with AF are underused and that the bleeding risk may be over-rated and/or
thrombo-embolic risk under-estimated. However, specific risk factors in older
patients may not be included in currently used scores.
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Introduction: Characteristics of patients with atrial fibrillation (AF) are
well known, however the patients included in published studies are usually
younger than patients encountered in daily practice in hospital.
Anticoagulation
=74
o anticoagulation
=68
p
Age (years) 81.8±0.5 84.6±0.6 0.001
Creatinine (µmol/l) 106±7.3 127.3±6.3 0.03
Dependency (%) 27 54 0.001
Dementia (%) 4,1 14,7 0.04
High risk of falling (%) 0 20 0,001
MMS score 21.4±1.2 20.1±1.1 NS
ADL score 5.1±0.3 3.8±0.4 0.001
IADL score 2±0.2 2.4±0.4 NS
OAC o OAC
T (CHADS) >B 49.2% 39%*
T (CHADS) < B 2.3%µ 9.2%
T (CHADSVASC) >B  47%  40%*
T (CHADSVASC) < B 3.8%µ 8.4%
T: Thrombo-embolic risk; B: bleeding risk (HASBLED) according to scores
*: undertreated patients according to scores
µ: over-treated patients according to scores
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Method: We performed a prospective observational study which aimed to
describe all patients over 75 years hospitalized in a cardiology department. For
each patient we collected cause of hospitalisation, medical and cardiovascular
history. We compared patients with and without previous history of AF (“AF
group” versus “sinus group”).
Results: Among 1050 patients admitted during an inclusion period of
4 months, 357 patients were older than 75 years: 150 in the “AF group” and
207 in the “sinus group”. AF was paroxysmal, persistent and permanent
respectively in 21%, 30%, and 48% of cases.
Table – Main data
Conclusion: Patients over 75 years of age accounted for 34% of patients
admitted in our cardiology department and 42% of them had a history of atrial
fibrillation.
AF patients had more frequently valvular disease, thyroid dysfunction,
which are comorbidities associated with AF but also more strokes, dementia
and hospitalization for heart failure which may be consequences of AF.
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The risk of atrial fibrillation (AF) in patients with paroxysmal supraventric-
ular tachycardia (SVT) is well-known. AF is a cause of embolic event and a
risk of stroke in patients with SVT can be expected. The purpose of the study
was to assess the prevalence of unexplained stroke in patients presenting with
SVT and to look for the risk factors.
Methods: Electrophysiological study (EPS) was performed in 1379 patients
without anterograde conduction through accessory pathway (AP) for SVT.
Clinical and electrophysiological data were collected.
Results: Stroke was noted in 38 patients (group I) (prevalence 2.8%).
1341 patients had no stroke (group II). 1) Clinical data: Group I was older
than group II (62±13 vs 49±19 years) (p<0.0002). Associated heart disease
(14/38, 37% vs 139/1341, 10%)(p<0.0001), AF history (4/38, 10.5%, 32/1341,
2%, p<0.002) were more frequent in group I than in group II. Male gender
was similar in both groups. 2) Electrophysiological data: SVT mechanism
was similar: AV re-entrant tachycardia in a concealed AP was noted in 4
group I patients (10.5%) and 247 group II patients (18%)(NS). Signs of atrial
vulnerability were as frequent in both groups. 3) Follow-up (mean 3±3 years):
Adverse events (AE) occurred in 102 patients: 3 group II patients presented a
stroke; AF occurred in 8 group I patients (21%), 62 group II patients
(5%)(p<0.0001); 3 group I patients (8%), 26 group II patients (2%) died from
cardiovascular death (p<0.01). SVT ablation was performed in 65 of
102 patients (64%) with AE (AF or death), 790 of 1277 patients without AE
(62%)(NS). Age (p=0.001), prior AF (p=0.001) were the 2 independent risk
factors of stroke at multivariate analysis stroke. Adjusted on age, heart disease
was not significantly associated with stroke.
Conclusions: Unexplained stroke was a rare event in patients with paro-
xysmal SVT (2.8%). Old age, and AF history were the only independent sig-
nificant factors associated with the history of stroke in these patients. They
had a risk of severe adverse events during the follow-up as spontaneous AF
(21%) or death (8%). SVT ablation did not reduce the risk of new stroke,
spontaneous AF or death.
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Introduction: Catheter ablation has emerged as a realistic therapeutic
option for symptomatic atrial fibrillation (AF). Young patients with AF are
often more symptomatic and long-term taking medication is very demanding
for their daily life. The aim of our study is to describe the safety and the long-
term effectiveness of catheter ablation of AF in patients under 30 years of age.
Methods and results: Twenty five consecutive patients < 30 years old
(mean age: 26±3; 16-29) with paroxysmal (13 pts, 52%) or persistent AF
(12 pts, 48%, AF duration 40±24 months) underwent catheter ablation of
symptomatic atrial fibrillation refractory to at least one antiarrythmic drug
(AAD), in our center. Only 3 patients had structural heart disease (hypertro-
phic cardiomyopathy). Patients were hospitalized and monitored at 3, 6 and 12
months, every 6 months thereafter and at the end of the follow up. Mean radio
frequency duration was 51±29 min (39±14 for PAF and 65±40 for PsAF) for
total procedure time of 176±91 min (128±55 for PAF and 224±100 for PsAF)
and a fluoroscopic time of 52±33 min (38±20 for PAF and 62±36 for PsAF).
In all procedures, no major complication occurred. After a mean follow up of
54 months ± 29; 21/25 (84%) patients remained arrhythmia-free (92% for
PAF and 76% for PsAF) after a mean of 1.6 procedure per patient. 19 of the
21 arrhythmia free patients were also AAD free. Only 3 patients of these
21 patients were treated with warfarin.
Conclusion: These finding suggest that catheter ablation of AF in patients
under 30 years of age is safe, with good clinical long term outcome. Catheter
ablation of AF can be first-line therapy in young people.
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TOTAL
=357
AF group 
=150 (42%)
Sinus group
=207(58%)
p
Age 82±13 83±13 81±11 0.03 
Men 186 75 (50) 106 (51.2) 0.9
HTA 178 (50) 76 (50.7) 102 (49.5) 0.9
Diabetes 86 (24.1) 35 (23.3) 51 (24.7) 0.1
Dyslipemia 93 (26.1) 35 (23.3) 58 (28.2) 0.3
Ischemic heart 
disease
13 (38.8) 55 (36.7) 83 (40.3) 0.1
Respiratory failure 26 (7.28) 13 (8.6) 13 (6.28) 0.4
Valvular heart disease 38 (10.5) 20 (13.3) 18 (8.73) 0.04
Pulmonary embolism 20 (5.6) 13 (8.6) 7 (3.3) 0.02
AVC 39 (10.9) 23 (15.3) 16 (7.7) 0,01
Thyroid disease 32 (8.9) 18 (12) 14 (6.7) 0.03
Dementia 23 (6.5) 13 (8.7) 10 (4.9) 0.1
Alcoholism 11 (3) 10 (6.7) 1 (0.48) 0.01
Main cause of
hospitalisation
   
Cardiac heart failure 111 (31) 67 (44.7) 44 (21.4) <0.001
Acute coronary 
syndrome
67 (19) 11 (7.3) 56 (26.6) <0.001 
